(11 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{UPMC_PARIS}} | {{UPMC_PARIS}} | ||
− | <html> | + | <html style="text-align: justify;"> |
− | + | ||
− | + | ||
<!-- ==== SECTION DIVIDER1 --> | <!-- ==== SECTION DIVIDER1 --> | ||
− | <style media="screen"> | + | <style media="screen"> |
− | .img-tmplate{ | + | .img-tmplate{ |
− | + | background-image: url(https://static.igem.org/mediawiki/2017/c/c2/UPMC_111.jpeg); | |
− | } | + | } |
− | .img-tmplate .container h1, .img-tmplate .container p{ | + | .img-tmplate .container h1, .img-tmplate .container p{ |
− | + | color: #344c82; | |
− | } | + | } |
− | </style> | + | .img-tmplate { |
− | <section class="section-divider textdivider divider1 img-tmplate"> | + | height: 450px; |
− | + | } | |
− | + | </style> | |
− | + | <section class="section-divider textdivider divider1 img-tmplate"> | |
− | + | <div class="container"> | |
− | </section><!-- section --> | + | <!--<h1 style="color:#424242;margin-left:200px">UPMC PARIS</h1>--> |
+ | |||
+ | </div><!-- container --> | ||
+ | </section><!-- section --> | ||
Line 26: | Line 27: | ||
<br> | <br> | ||
<div class="row"> | <div class="row"> | ||
− | <h2 class="centered"> | + | <h2 class="centered">Entrepreneurship</h2> |
<hr> | <hr> | ||
− | + | <div class="container" id="services" name="services" style="text-align: justify;"> | |
<p> | <p> | ||
Days after days, the recombinant proteins production is growing as a vital industrial science, in major fields of work such as healthcare or agronomy. Optimization of this production, that to says reducing the cost and time of production of these molecules, is the main priorty of companies of this sector. Another major challenge remain to further automatize these processes. | Days after days, the recombinant proteins production is growing as a vital industrial science, in major fields of work such as healthcare or agronomy. Optimization of this production, that to says reducing the cost and time of production of these molecules, is the main priorty of companies of this sector. Another major challenge remain to further automatize these processes. | ||
Line 59: | Line 60: | ||
<br> | <br> | ||
<embed src="https://static.igem.org/mediawiki/2017/5/59/UPMC_team_2017_Entrepreunership_access_to_healthcare.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | <embed src="https://static.igem.org/mediawiki/2017/5/59/UPMC_team_2017_Entrepreunership_access_to_healthcare.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | ||
+ | |||
+ | <div class="container" id="services" name="services" style="text-align: justify;"> | ||
− | |||
</div><!-- row --> | </div><!-- row --> | ||
Line 112: | Line 114: | ||
<div class="row"> | <div class="row"> | ||
<h4 class="centered">Drug candidates</h4> | <h4 class="centered">Drug candidates</h4> | ||
− | <div class=" | + | <div class=""> |
<br> | <br> | ||
<p> | <p> | ||
Line 127: | Line 129: | ||
<embed src="https://static.igem.org/mediawiki/2017/e/ec/UPMC_team_2017_Entrepreunership_treatments.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | <embed src="https://static.igem.org/mediawiki/2017/e/ec/UPMC_team_2017_Entrepreunership_treatments.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | ||
<br> | <br> | ||
+ | <div class="container" id="services" name="services" style="text-align: justify;"> | ||
<p> | <p> | ||
We have presented here the pathologies illustrating the most the mortality due to the lack of access to healthcare. However, we can imagine that our box can also respond to certain chronic conditions. Besides, we should not forget that our box is not a frozen project. Around its role of automated production and purification, it leaves a large room for its optimization and allows us to work on a decreased production time and an increased quantity of proteins production. The possible optimization of the box could also revolve in the creation of a more or less storage, an ephemeral method to compensate for the time variable of production. It should be noted that this box is also a solution to the ethical problems related to obtaining of some serum proteins from animal immunization or for the production of hormones. In this way, it would be a solution to the problem of immunogenicity of these serotherapies in humans. | We have presented here the pathologies illustrating the most the mortality due to the lack of access to healthcare. However, we can imagine that our box can also respond to certain chronic conditions. Besides, we should not forget that our box is not a frozen project. Around its role of automated production and purification, it leaves a large room for its optimization and allows us to work on a decreased production time and an increased quantity of proteins production. The possible optimization of the box could also revolve in the creation of a more or less storage, an ephemeral method to compensate for the time variable of production. It should be noted that this box is also a solution to the ethical problems related to obtaining of some serum proteins from animal immunization or for the production of hormones. In this way, it would be a solution to the problem of immunogenicity of these serotherapies in humans. | ||
Line 189: | Line 192: | ||
<embed src="https://static.igem.org/mediawiki/2017/a/a7/UPMC_team_2017_Entrepreunership_swot.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | <embed src="https://static.igem.org/mediawiki/2017/a/a7/UPMC_team_2017_Entrepreunership_swot.pdf" width="100%" style="margin-left:auto;margin-right:auto;" height="1000" type='application/pdf'> | ||
+ | <br> | ||
+ | <h2 class="content-title">Buisness Plan</h2> | ||
+ | <hr> | ||
+ | |||
+ | <br> <br> | ||
+ | <img class="img-responsive" src="https://static.igem.org/mediawiki/2017/9/9a/UPMC_team_2017_buisness_plan.jpg" alt=""> | ||
</div><!-- col-lg --> | </div><!-- col-lg --> | ||
Line 197: | Line 206: | ||
<div id="footerwrap"> | <div id="footerwrap"> | ||
− | + | <style media="screen"> | |
− | + | #footerwrap { | |
− | + | background: #ffffff; | |
− | + | color: black; | |
− | + | } | |
− | + | #footerwrap h4,#footerwrap h3{ | |
− | + | color: black; | |
− | + | } | |
− | + | </style> | |
− | + | <div class="container"> | |
− | + | <div class="col-sm-12"> | |
− | + | <br> | |
− | + | <h3>Sponsors</h3> | |
− | + | <br><br><br> | |
− | + | <div class="row"> | |
− | + | <div class="col-sm-3"> | |
− | + | <img height="40%" width="40%" src="https://static.igem.org/mediawiki/2017/8/84/UPMC_team_2017_sponsors_FSDIE.jpg" alt=""> | |
+ | </div> | ||
+ | <div class="col-sm-3"> | ||
+ | <img height="30%" width="30%" src="https://static.igem.org/mediawiki/2017/5/54/UPMC_team_2017_sponsors_Ambassade_france.jpg" alt=""> | ||
+ | </div> | ||
+ | <div class="col-sm-3"> | ||
+ | <img height="30%" width="30%" src="https://static.igem.org/mediawiki/2017/4/4e/UPMC_team_2017_sponsors_Bagneux.jpg" alt=""> | ||
+ | </div> | ||
+ | <div class="col-sm-3"> | ||
+ | <img height="30%" width="30%" src="https://static.igem.org/mediawiki/2017/d/d5/UPMC_team_2017_sponsors_ICM.png" alt=""> | ||
+ | </div> | ||
</div> | </div> | ||
− | <div class="col-sm-3"> | + | <br> |
− | <img height="30%" width="30%" src=" | + | <div class="row"> |
+ | <div class="col-sm-3"> | ||
+ | <img height="60%" width="60%" src="https://static.igem.org/mediawiki/2017/b/be/UPMC_team_2017_sponsors_UPMC.png" alt=""> | ||
+ | </div> | ||
+ | <div class="col-sm-3"> | ||
+ | <img height="30%" width="30%" src="https://static.igem.org/mediawiki/2017/7/70/UPMC_team_2017_sponsors_IDT.png" alt=""> | ||
+ | </div> | ||
+ | <div class="col-sm-3"> | ||
+ | <img height="30%" width="30%" src="https://static.igem.org/mediawiki/2017/5/5b/UPMC_team_2017_sponsors_NEB.png" alt=""> | ||
+ | </div> | ||
+ | <div class="col-sm-3"> | ||
+ | <img height="50%" width="50%" src="https://static.igem.org/mediawiki/2017/6/6d/UPMC_team_2017_sponsors_T-Evry_Paris-Saclay-logos-sponsors-sigma.png" alt=""> | ||
+ | </div> | ||
</div> | </div> | ||
− | < | + | <br> |
− | + | <div class="row"> | |
− | + | <div class="col-sm-3"> | |
− | + | <img src="https://static.igem.org/mediawiki/2017/d/de/UPMC_team_2017_sponsors_CFA_UPMC.png" alt=""> | |
− | + | </div> | |
− | + | <div class="col-sm-3"> | |
− | + | <img height="40%" width="40%" src="https://static.igem.org/mediawiki/2017/e/e8/UPMC_team_2017_sponsors_Valenton.png" alt=""> | |
− | + | </div> | |
− | + | <div class="col-sm-2"> | |
− | + | <img height="100%" width="100%" src="https://static.igem.org/mediawiki/2017/d/df/UPMC_team_2017_sponsors_Logo_Paillasse.jpg" alt=""> | |
− | + | </div> | |
− | + | <div class="col-sm-2"> | |
− | + | <img height="100%" width="100%" src="https://static.igem.org/mediawiki/2017/b/bf/UPMC_team_2017_sponsors_MAster_BMC.jpg" alt=""> | |
− | + | </div> | |
− | + | <div class="col-sm-2"> | |
− | + | <img height="100%" width="100%" src="https://static.igem.org/mediawiki/2017/8/80/UPMC_team_2017_sponsors_UFR_bio.jpg" alt=""> | |
− | + | </div> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</div> | </div> | ||
</div> | </div> | ||
+ | |||
</div> | </div> | ||
− | |||
</div> | </div> | ||
− | |||
</html> | </html> |
Latest revision as of 00:11, 19 December 2017
Entrepreneurship
Days after days, the recombinant proteins production is growing as a vital industrial science, in major fields of work such as healthcare or agronomy. Optimization of this production, that to says reducing the cost and time of production of these molecules, is the main priorty of companies of this sector. Another major challenge remain to further automatize these processes.
When we started the project our main goal was to find a solution that could help to resolve the issues of the lack of access to proper healthcare in developing contries. To do so, we investigated the causes of the healthcare failures in different regions of the world that leads to a lower life span compared to developed countries. Beyond a lack of basal hygienic prevention in an environment often favourable to the growth of various pathogenic agents, the lack of access to healthcare appeared as an obvious source of this lower quality of health.
Through our box, we focused more specifically on the lack of access to preventive and curative protein drugs. We want to innovate in the way we produce already existing therapeutic molecules.
We then focused on 3 main causes of the lack of access to drugs in the world :
1) The lack of financial means for the purchase and setting up of drug production
2) Geographical isolation of the countries concerned
3) Storage and transport of drugs issues
Strategic Business Unit (SBU)
In order to have a more general view of the drug market, we have set up a SBU table around the question of the lack of access to healthcare.